A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer

NCT07676162 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
DRUG: Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.